Better Choice Acquires Choice Specialty Pharmacy (~6x EBITDA)
- Will Hamilton
- Mar 12, 2025
- 2 min read
Updated: 1 day ago
On March 11, 2025, Better Choice Company, Inc. (NYSE American: BTTR) signed a binding Letter of Intent to acquire 100 % of Choice Specialty Pharmacy Group, a fully licensed U.S. provider of specialty pharmacy and infusion clinic services with an integrated sterile compounding facility, under an option purchase agreement. The transaction, which is expected to close later in 2025 following exercise of the option, strengthens Better Choice’s footprint in healthcare services alongside its recently expanded SRx Health platform and provides a strategic entry point into high‑growth segments of the pharmacy market.
Choice, founded in 2015 and operating across multiple states, offers specialized dispensing and care coordination for complex, chronic and rare conditions, expanding Better Choice’s capabilities in both U.S. specialty pharmacy and sterile compounding operations. The acquisition is intended to accelerate Better Choice’s strategy of building a North American healthcare services company with significant market share, leveraging operational synergies, expanded geographic reach and enhanced care offerings between the U.S. and Canada. The deal also aligns with broader industry trends toward consolidation in specialty pharmacy and value‑based care delivery, areas characterized by durable demand and higher‑margin service lines.
Pharmacy / Infusion EBITDA Multiples
The purchase price is based on approximately 6x Choice’s FY 2024 adjusted EBITDA of $4.68 million, implying a purchase price of $28 million, with consideration to be comprised of a mix of stock and cash at closing.
Pharmacy / Infusion M&A Deal Volume
About Scope Research
The Scope Research Healthcare M&A Valuation Database currently has financial details related to 83 pharmacy and infusion therapy deals, segmented by type, including 70 deals with disclosed EBITDA multiples. The data can be purchased individually, while our affordable annual subscriptions provide access to all of our healthcare M&A databases and segments, updated continuously.
Don't hesitate to reach out to Will Hamilton at will@scoperesearch.co with questions about your specific situation.